Compare AU
Compare IOZ vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the iShares Core S&P/ASX 200 ETF (IOZ) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IOZ | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 712 | 80 |
Median incremental investment | $1,005.91 | $620.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,508.42 | $1,325.53 |
Average age group | 26 - 35 | > 35 |
Key Summary
IOZ | CURE | |
|---|---|---|
Strategy | The fund seeks to track the performance of the S&P/ASX 200 Accumulation Index before considering fees, expenses, and taxes. The index consists of the 200 largest Australian securities listed on the ASX. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | COMMONWEALTH BANK OF AUSTRALIA (10.37 %) BHP GROUP LTD (8.18 %) CSL LTD (5.36 %) | Neurocrine Biosciences Inc (2.75 %) Alnylam Pharmaceuticals Inc (2.52 %) Insmed Inc (2.46 %) |
Top 3 industries | Financials (33.17 %) Materials (18.17 %) Health Care (8.64 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (94.85 %) United States (3.08 %) New Zealand (1.58 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.05 % | 0.45 % |
Key Summary
IOZ | CURE | |
|---|---|---|
Issuer | iShares | Global X |
Tracking index | S&P ASX 200 | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.05 % | 0.45 % |
Price | $33.84 | $50.44 |
Size | $6.698 billion | $34.226 million |
10Y return | 35.31 % | N/A |
Annual distribution yield (5Y) | 5.33 % | 4.24 % |
Market | ASX | ASX |
First listed date | 09/12/2010 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IOZ | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 712 | 80 |
Median incremental investment | $1,005.91 | $620.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,508.42 | $1,325.53 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
IOZ | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
IOZ | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |